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ABSTRACT 
Objective 
Asthma is a chronic pulmonary disease with multiple triggers manifesting as symptoms with various intensities. This                
paper evaluates the suitability of long-term monitoring of pediatric asthma using diverse data to qualify and quantify                 
triggers that contribute to the asthma symptoms and control to enable personalized management plan. 
 
Materials and Methods 
Asthma condition, environment, and adherence to the prescribed care plan were continuously tracked for 97               
pediatric patients using kHealth-Asthma technology for one or three months.  
 
Result  
At the cohort level, among 21% of the patients deployed in spring, 63% and 19% indicated pollen and Particulate                   
Matter (PM2.5), respectively, as the major asthma contributors. Of the 18% of the patients deployed in fall, 29%                  
and 21% found pollen and PM2.5 respectively, to be the contributors. For the 28% of the patients deployed in                   
winter, PM2.5 was identified as the major contributor for 80% of them. One patient across each season has been                   
chosen to explain the determination of personalized triggers by observing correlations between triggers and asthma               
symptoms gathered from anecdotal evidence. 
 
Discussion and Conclusion 
Both public and personal health signals including compliance to prescribed care plan have been captured through                
continuous monitoring using the kHealth-Asthma technology which generated insights on causes of asthma             
symptoms across different seasons. Collectively, they can form the underlying basis for personalized management              
plan and intervention. 
 
BACKGROUND AND SIGNIFICANCE 
Asthma is a chronic lung inflammatory disease affecting 26 million people in the USA, of which 6 million are children                    
[1]. It is a multifactorial disease with different triggers manifesting as asthma symptoms of various intensities which                 
demands a personalized diagnosis and management plan [2]. Infrequent clinical visits are unable to provide timely                
feedback and intervention as most of the asthma-exacerbating factors are pollutants from the patient’s environment               
[3] and lack of medication adherence [4]. Continuous tracking and assessment of a patient’s condition, environment,                
and adherence to a prescribed care plan can improve asthma control and quality of life [5]. 
 
While many studies have shown the effectiveness of continuous monitoring, only a few are being evaluated to                 
benefit traditional healthcare practices [6,7]. Propeller Health[8] provides personalized alerts based on inhaler usage              
and location to primarily improve medication adherence. ENVIROFI [9] and azma.com [10] send a notification to                
subscribed users when the outdoor environment forecast is poor. Chu et al [11] developed a ubiquitous warning                 
system which sends alerts to healthcare providers based on a patient's location if the outdoor environment is poor.                  
Finkelstein et al [12] developed a web-based approach that captures Forced Vital Capacity test and asthma                
symptoms from patients and sends alert to hospitals when these parameters are abnormal. AsthmaGuide [13], a                
home management ecosystem, enables doctors to observe the correlation between symptoms and environmental             
data. They have classified wheezing sounds as asthmatic wheezing and non-asthmatic wheezing. They also send               
personalized alerts to patients based on pollen and air quality forecast, but no causal relationships are identified.                 
However, while a number of factors has been shown to influence triggers and control level for an individual asthma                   
patient, monitoring and analyzing diverse data directly relevant to an individual patient has not been adequately                
evaluated.  
 
Using the kHealth-Asthma technology [14], we monitored and collected diverse data for a cohort of pediatric                
patients receiving asthma care at the Dayton Children’s Hospital (DCH). This paper presents cohort level               
preliminary data analysis for patients deployed in each of the seasons to identify the major contributors to asthma                  
symptoms. In addition to that, one patient was chosen from each season to illustrate the personalized trigger                 
determination by gathering anecdotal evidence. 
 
MATERIALS AND METHODS 
kHealth is a framework to personalize digital health by collecting and analyzing multimodal data that complement                
data collected during routine clinical care, specifically Patient Generated Health data using mobile app and sensors                
as well environmental data. It is designed to assist self-monitoring and self-appraisal of asthma care with an intent                  
to incorporate self-management, prediction, and intervention of asthma progression [15]. kHealth-Asthma is the             
adaptation of kHealth for asthma, and comprises of three components: kHealth kit, kHealth cloud, and kHealth                
Dashboard. The study design including these components, their use for data collection and the data analysis of the                  
97 patient cohort are discussed next. Other applications for which kHealth has been adapted include post-bariatric                
surgery monitoring, post-surgery monitoring of Acute Decompensated Heart Failure (ADHF), and dementia.  
 
kHealth Components 
 
kHealth  Kit 
The kHealth kit components are shown in Figure 1. The questionnaire presented by the mobile application on the                  
tablet collects the following data: (i) six types of symptoms: cough, wheeze, chest tightness, hard and fast breathing,                  
can’t talk in full sentences, and nose opens wide [16], (ii) medication intake (rescue inhaler and controller                 
medication) with yes or no option, (iii) night-time awakenings due to asthma symptoms, and (iv) activity limitation                 
due to asthma symptoms. The symptoms and medications are collected twice a day, and night-time awakenings                
and activity limitation are collected once a day (details in Appendix 1). Furthermore, Fitbit is used to collect more                   
granular data for sleep and activity [17]. The lung function measurements (PEF and FEV1) are recorded by the                  
Microlife peak flow meter [18] twice every day. For a given patient’s zip code, outdoor environmental parameters are                  
collected at different intervals -- pollen is collected every 12 hours, Particulate Matter (PM2.5), ozone, temperature,                
and humidity are collected every hour. Pollen is collected from pollen.com [19], PM2.5 and ozone from EPA                 
AIRNow [20], and temperature and humidity from Weather Underground [21]. Foobot collects indoor temperature,              
humidity, particulate matter, volatile compounds, carbon dioxide, and global pollution index every 5 minutes.              
Available literature have evaluated quality and suitability of Fitbit [22,23]. The feasibility study for Foobot has been                 
conducted on our own[24]. 
 
 
Figure 1: The kHealth framework with kHealth kit, kHealth cloud and kHealth Dashboard, showing the frequency of data                  
collection, the number of parameters collected and the total number of data points collected per day per patient.                  
(A-Dark Blue): The kHealth kit components that are given to patients, (B- Light Blue): The kHealth kit components which                   
collects patient generated health data, (C - Green): The outdoor environmental parameters and their sources, (D - Grey):                  
The kHealth cloud, (E): The kHealth Dashboard. Throughout the kHealth ecosystem, all data is anonymized and                
associated with respective randomly assigned patient IDs. 
 
kHealth Cloud 
The multimodal data collected from various sources are brought together on the secure kHealth cloud store. The                 
data about outdoor environment, indoor air quality, activity, and sleep data are collected from their respective API                 
server and stored directly in the kHealth cloud. The data collected using the kHealth application, which includes the                  
patient’s symptoms, medication intake, PEF and FEV1 readings, are synced in real-time with Firebase, a Google                
cloud database [25]. Firebase provides active data listener for client-side that offers data persistence over the                
network failure and resyncs to the cloud when the network is restored. Data security is maintained in Firebase using                   
a set of data access rules and user authentication. Data synced to Firebase are then fetched and stored into the                    
kHealth cloud. This process forms a pipeline for seamless data streaming from the kHealth application to the                 
kHealth cloud. All of the data stored in the kHealth cloud are then available to Kno.e.sis researchers and clinicians                   
for real-time analysis. Each patient’s identity is anonymized by the nurse who consents the patient; no                
patient-identifiable data is stored anywhere in the kHealth framework outside the clinical setting. 
 
kHealth Dashboard  
Since the kHealth kit collects multimodal data at different frequencies, integration and visualization of these data are                 
essential to derive useful insights. kHealth Dashboard [26] (Figure 2), is a visualization and analysis tool designed                 
for use by a clinician or a researcher to review individual and aggregated data, and to explore the potential causal                    
relationship between patient’s asthma symptoms and their environments. With real-time data available in the              
kHealth cloud, kHealth Dashboard allows real-time monitoring of a patient’s asthma condition. This granularity of               
data presents the clinician with a better picture about patient’s asthma condition compared to traditional episodic                
clinical visits.  
 
 
Figure 2: A screenshot of the kHealth Dashboard visualizing Patient-A’s data 
 
 
Study Design and Participants  
Pediatric asthma patients between 5 and 17 years of age receiving care at DCH were consented (with a                  
parent/guardian for very young children) and recruited by a DCH nurse coordinator under the guidance of the                 
clinician. Patient (and parent/guardian) were given training with demonstration and instruction materials. The tablet              
with Android application, Peak Flow meter, Fitbit and Foobot are given to patients and based on the patient’s zip                   
code, outdoor environmental data are collected. The part of data collection, which requires the patient to be actively                  
involved such as Android app questionnaire and Peak Flow meter readings, is referred to as active sensing. The                  
data collection from Fitbit, Foobot and outdoor web services, which do not require active patient involvement, is                 
referred to as passive sensing. 
 
Of the 100 patients consented in the ongoing trial at the time of this manuscript submission, 97 patients had                   
completed the trial and 3 were in progress. Out of 97 patients, 80 were recruited for a month and 17 were recruited                      
for 3 month period. The one month study was designed to validate the efficacy of this method and three month                    
study was included to focus on intervention as three month is the standard duration between two clinical visits to                   
adjust medication based on control level. The enrollment of a patient for one or three months depends on their                   
willingness. This HIPAA compliant study has been approved by DCH’s institutional review board. While the               
deployments started in December 2016 and is still ongoing, the data from December 2016 to July 2018 is included                   
in the analysis. 21 patients were excluded from the analysis due to insufficient active sensing (less 20%), allowing                  
us to analyze data from the remaining patients (n=76). 
 
RESULT AND DISCUSSION 
Henceforth, the six asthma symptoms (cough, wheeze, chest tightness, hard and fast breathing, can’t talk in full                 
sentences, nose opens wide), night-time awakenings, activity limitation, rescue medication intake, and abnormal             
PEF/FEV1 value are collectively referred to as asthma episodes​. Specifically, asthma can cause lung function to                
decline and can manifest as lower values for PEF and FEV1 parameters [27]. Therefore, the reduction of PEF and                   
FEV1 values beyond 1 standard deviation of the mean were treated as episodes of asthma. The duration of the                   
seasons has been chosen to aid the analysis based on the historical pollen data (Figure 3). The results of cohort                    
level data analysis are shown in Figure 3 for the detection of a wide variety of triggers and causes of asthma                     
episodes.  
 
 
 
Figure 3: Personalized  (Major) Triggers at the Cohort Level 
 
One patient with poorly controlled asthma was chosen for each season for illustration. As such, two cases                 
containing adequate data but poor kit compliance have been included. Patient-A’s deployment period straddled two               
seasons, winter to spring, which permitted the study of asthma’s behavior both in the presence and in the absence                   
of pollen. The other three patients were exclusively within one season: Patient-B in winter, Patient-C in fall, and                  
Patient-D in summer. The days the patients did not answer the questionnaire were excluded from the analysis.                 
Each patient’s deployment period was divided into two: a learning period and a prediction period. The data from the                   
learning period was used to learn the causal association between the patient’s asthma episodes and triggers. The                 
data from the prediction period was used to evaluate the ability to predict the likelihood of an episode based on the                     
presence of the triggers. Ultimately, once a reliable personalized model associating triggers with asthma episode is                
attained, it can be used to guide plausible action plan including preventive or remedial measures, as well as further                   
targeted evaluations to help develop better personalized care.  
 
Maximum values of outdoor environmental data (ozone, PM2.5) over a day were considered to identify the                
correlation between triggers and asthma episodes. The healthy range for each outdoor parameters are -- Pollen                
[28]: 0 to 2.4, Ozone and PM2.5 [29]: 0 to 50. Any value above or below the healthy range on the day with asthma                        
episodes, or the previous day, is counted as a contributor to the patient’s asthma episodes. While we collected                  
extensive Foobot data, the results on the influence of indoor environment are inconclusive, potentially because of a                 
number of deficiencies in our instructions such as (a) clarity on the placement of Foobot, and (b) potential for                   
electrical interference, when some patients did not power the device as required by the manufacturer. In the study                  
results recorded thus far, the outside environment provides more reliable signals for asthma control. Further, the                
sleep and activity data from Fitbit did not provide corroborative evidence for asthma signs due to several                 
confounding factors. In contrast, self-reported data obtained through the Android app based questionnaire proved to               
be more reliable. We analyze concrete patient cases to obtain insights about asthma triggers, patient behavior and                 
their condition from evidences collected by kHealth-Asthma technology in different seasons. 
 
Winter to Spring  
Patient-A was diagnosed with severe asthma, and monitored for 13 weeks encompassing winter to spring 2018 and                 
answered the questionnaire for 46 days. The patient was prescribed Albuterol and Atrovent (as rescue medication),                
and Dulera and Singulair (as controller medication). The patient took rescue medication for 24 days, experienced                
cough, wheeze or chest tightness for 39 days, had limited activity for 26 days, abnormal PEF/FEV1 for 2 days and                    
was 15% compliant in taking controller medication.  
 
As pollen was absent in the first half of the deployment period and present in the second half, the deployment                    
period was divided and evaluated for two periods: first 6 weeks without pollen, and last 7 weeks with pollen. The                    
patient’s reaction to ozone and PM2.5 manifesting as asthma episodes were also studied separately during these                
two periods to disambiguate among multiple triggers. The 6 weeks without pollen was further divided into two                 
sub-periods: first 4 weeks as the learning period and rest (2 weeks) as the prediction period. Similarly, the 7 weeks                    
without pollen was further divided into 4 weeks as the learning period and 3 weeks as the prediction period. 
 
Table 1. Learning causal associations and Prediction of Asthma episodes for Patient-A 
Absence of Pollen 
First 6 weeks 
Presence of Pollen 
Rest of the 7 weeks 
Learning 
4 weeks 
Prediction 
2 weeks 
Learning 
4 weeks 
Prediction 
3 weeks 
Pollen 0 days Pollen 0 days Pollen 17 days Pollen 3 days 
PM2.5 20 days PM2.5 5 days PM2.5 14 days PM2.5 2 days 
Ozone 1 day Ozone 0 days Ozone 0 days Ozone 1 day 
Asthma 
episodes 
21 days Asthma 
episodes 
5 days Asthma 
episodes 
17 days Asthma 
episodes 
3 days 
Outdoor Temperature:  ​​7 to 55 F Outdoor Temperature: ​​30 to 75F 
Outdoor Humidity: ​​20 to 98 % Outdoor Humidity: ​​20 to 99% 
 
In the absence of pollen, PM2.5 appeared as the major contributor of asthma episodes (shown in Table 1). During                   
the prediction period, PM2.5 was high on the days the patient reported symptoms. It can be inferred that PM2.5 is                    
one of the contributors of the patient’s asthma episodes as other triggers were in the healthy range. Similarly, in the                    
presence of pollen, pollen was the major contributor and PM2.5 was the second major contributor. During the                 
prediction period, both pollen and PM2.5 were high on almost all the days the patient reported asthma episodes.                  
Though the patient showed asthma episodes both in the presence and in the absence of pollen, the patient started                   
experiencing severe symptoms only in the presence of pollen. The patient experienced 6 out of 9 occurrences of                  
chest tightness (chest tightness is more severe than cough or wheeze) and 6 out of 7 occurrences of night                   
awakenings in the presence of pollen. For this patient, the presence of pollen or PM2.5 in the unhealthy range                   
appears to be prime contributing factor for asthma episodes, and the combined presence is associated with                
increased intensity of asthma episodes. When validated with the clinician, the patient was identified allergic to pollen                 
using skin test. The Asthma Control Test scores before and after the deployment confirm that the patient’s asthma                  
control was suboptimal. 
 
Through continuous monitoring, we found that PM2.5 and pollen were the contributors to the patient’s asthma                
episodes, and the patient had poor adherence to controller medication. To improve asthma management, the               
intervention can be personalized by alerting patient about high pollen and PM2.5 forecast. Further, notification can                
be sent to improve the compliance for controller medication. If asthma episodes recur even after being compliant                 
toward controller medication, the clinician can intervene with the modified asthma action plan. 
 
Winter 
Patient-B was classified as having moderate asthma and monitored for 13 weeks in winter 2017 to 2018. But data                   
from only the first 9 weeks was available for analysis as the patient didn’t answer for 4 weeks towards the end of the                       
deployment. The patient was prescribed Albuterol (as rescue medication) and Singulair (as controller medication),              
and answered the questionnaire for 50 days of which the patient experienced asthma episodes for 45 days.                 
Patient-B experienced wheezing for 27 days, activity limitation for 15 days, night-time awakenings on 1 day, took                 
rescue medication for 24 days, had abnormal PEF/FEV1 values for 6 days, and was 50% compliant toward                 
controller medication. Since the environment was uniform throughout the deployment, first 6 weeks were used to                
determine the triggers, and the last 3 weeks were used for prediction. 
 
Table 2. Learning causal associations and Prediction of Asthma episodes for Patient-B 
Learning 
6 weeks 
Prediction 
3 weeks 
Pollen 0 days Pollen 0 days 
PM2.5 21 days PM2.5 19 days 
Ozone 0 days Ozone 0 days 
Asthma episodes 24 days Asthma episodes 21 days 
Outdoor Temperature: ​​19 F to 60 F Outdoor Temperature: ​​-2 F to 58 F 
Outdoor Humidity: ​​17% to 99% Outdoor Humidity: ​​25% to 99% 
 
As shown in Table 2, PM2.5 was found to be the major contributor. When the findings were applied to predict the                     
asthma episodes, PM2.5 was bad for 19 days and patient experienced asthma episodes for 21 days. Specifically,                 
for the 2 days the patient experienced asthma episodes, none of the outdoor parameters were high on that day or                    
the previous day. However, it was observed that PM2.5 was consistently high for a week before the 2-3 days of                    
asthma episodes. The effect of prolonged exposure to high PM 2.5 can explain persistent airway hyper-reactivity                
and thereby asthma episodes. It is desirable to continue further evaluations to understand the triggers in other                 
seasons. 
 
In consequence, the patient can be proactively notified when PM2.5 is forecasted to be in the unhealthy range and                   
may also be reminded to take prescribed medication. To enhance the asthma management, the patient can improve                 
compliance toward controller medication and avoid exposure to PM2.5 when it is high. If this does not help, the                   
patient should be reevaluated to adjust the asthma control plan. 
 
Fall 
Patient-C was diagnosed with moderate asthma and monitored for 5 weeks and 4 days in the fall of 2017. The                    
patient answered the questionnaire 33 out of 36 days of deployment, of which the patient showed asthma episodes                  
for 17 days. The patient was prescribed Albuterol (as rescue medication), Symbicort and Singulair (as controller                
medications), and Prednisone (oral steroid). The patient had cough and wheeze for 11 days, had activity limitation                 
for 4 days, took rescue medication for 6 days, showed abnormal PEF/FEV1 for 9 days, and had compliance toward                   
controller medication of 63%. The outdoor environment remained uniform with respect to pollen, ozone, and PM2.5                
throughout the deployment. First 4 weeks of data were used for learning and the rest were used for prediction. 
 
Table 3. Learning causal associations and Prediction of Asthma episodes for Patient-C 
Learning Period 
4 weeks 
Prediction Period 
1 week and 4 days 
Pollen 11 days Pollen 10 days 
PM2.5 8 days PM2.5 10 days 
Ozone 2 days Ozone 6 days 
Asthma episodes 12 days Asthma episodes 5 days 
Outdoor Temperature: ​​65 F to 85 F Outdoor Temperature: ​​55 F to 80 F 
Outdoor Humidity: ​​70% to 90% Outdoor Humidity: ​​50% to 98% 
 
For this patient, pollen was found to be the major contributor and PM2.5 was the second major contributor (shown in                    
Table 3). But the patient experienced asthma episodes only for 5 days in the prediction period. This could be both                    
due to the improved compliance with controller medication up from 44% in the learning period to 100% in the                   
prediction period, and improved control of airway inflammation by oral steroid intake for a week in the learning                  
period.  
 
kHealth system has the potential to aid Patient-C in self-management of asthma by alerting the patient when pollen                  
or PM2.5 can exacerbate asthma and reminding the patient to take medication to improve compliance. Further, the                 
clinician can also be notified when the patient takes the oral steroid, an indication of poor asthma control, to enable                    
timely intervention. To exonerate some triggers and identify triggers precisely, the experiment should be repeated in                
the season when pollen is absent.  
 
 
Summer 
Patient-D has mild asthma, and was monitored for 4 weeks and 3 days in the summer of 2018. The patient was                     
prescribed Albuterol (as rescue medication), Asmanex and Singulair (as controller medications). Patient-D has             
answered the questionnaire for 29 out of 30 days and experienced asthma episodes on 6 days. The patient                  
experienced cough, wheeze, chest tightness, or hard and fast breathing for 5 days, activity limitation on 1 day,                  
night-time awakening on 1 day, and the compliance toward the controller medication was 70%. The lung function                 
measurements were normal throughout the study period. Out of the 6 days the patient showed asthma episodes,                 
pollen was in an unhealthy range for 3 days, ozone for 4 days, and PM2.5 on 6 days. Based on the observation,                      
PM2.5 is suspected to be the major contributor, followed by ozone and pollen. However, this patient had sparse                  
asthma episodes to build a predictive model for the asthma behavior. In general, none of the patients deployed in                   
summer had sufficient asthma episodes to learn a predictive model for the positive triggers of the episodes.  
 
CONCLUSION 
The infrequent clinical visit as practiced by traditional healthcare protocol is unable to provide timely feedback and                 
enable intervention. Through continuous monitoring, kHealth kit is able to provide detailed insights to the clinician                
about the personalized triggers for asthma patients and their compliance toward the prescribed asthma control               
protocol. Specifically, for patients like patient-A that spanned two seasons, the kHealth kit determined the triggers                
precisely along with the patient’s adherence to the prescribed asthma action plan. This can aid the clinician in                  
tailoring the asthma control protocols for a patient leading to better asthma management. Further kHealth kit was                 
able to capture triggers across different seasons, which was evident from the determination of the variety of                 
personalized triggers for 4 example patients chosen across the different seasons. 
 
FUTURE WORK 
We plan to repeat the observational trial across different seasons for each patient. Of 76 patients, 27% (n=20) of                   
the patients monitored in winter, and 29% (n=22) of the patients monitored in fall and in spring experienced asthma                   
episodes. Redeployment will be carried out for winter patients to discover potential triggers in other seasons, and                 
also for spring and fall patients to disambiguate among multiple triggers by exonerating some. For 9% (n=7) of the                   
patients, the deployment spanned across two seasons, yielding sparse data and hence insufficient for any reliable                
conclusion. Deployment for this subgroup will be attempted again, and one month deployments that span across                
two seasons will be avoided in future. 25% (n=19) of the entire patient cohort didn’t experience any asthma                  
episodes. Eventually, with the kHealth system, we expect to identify triggers across seasons for each patient that                 
cause worsening of the patient’s asthma and aid the clinician with insights about triggers and patient compliance for                  
personalized action plan. This study has also provided insights that can help design future study involving self                 
management and intervention. For such a study, some of the less important data types will be dropped and a                   
version of the kHealth Dashboard will be developed for use by patients that has customizable functionality, look and                  
feel. 
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LEGEND 
 
Figure 1: The kHealth framework with kHealth kit, kHealth cloud and kHealth Dashboard, showing the frequency of                 
data collection, the number of parameters collected and the total number of data points collected per day per                  
patient. (A-Dark Blue): The kHealth kit components that are given to patients, (B- Light Blue): The kHealth kit                  
components which collects patient generated health data, (C - Green): The outdoor environmental parameters and               
their sources, (D - Grey): The kHealth cloud, (E): The kHealth Dashboard. Throughout the kHealth ecosystem, all                 
data is anonymized and associated with respective randomly assigned patient IDs. 
 
Figure 2: A screenshot of the kHealth Dashboard visualizing Patient-A’s data 
 
Figure 3: Personalized  (Major) Triggers at the Cohort Level 
 
Table 1. Learning causal associations and Prediction of Asthma episodes for Patient-A 
 
Table 2. Learning causal associations and Prediction of Asthma episodes for Patient-B 
 
Table 3. Learning causal associations and Prediction of Asthma episodes for Patient-C 
______________________________________________________________________________ 
 
SUPPLEMENTARY TEXT  
Appendix 1: The questionnaire from kHealth Asthma Android application 
Question Answer type 
Did you experience any of the asthma symptoms? Cough, Wheeze, Chest tightness, Hard and Fast 
breathing, Can’t talk in full sentences, Nose opens 
wide  
How many times did you take ​[name of the rescue 
inhaler prescribed]​ inhaler today due to asthma 
symptoms? 
1,2,3,4,5,6+ 
Did you take ​[name of the controller medication 
prescribed]​ today? 
Yes, No 
How much did asthma symptoms limit your activity? None, A little, Most of the day, At least half of the day 
Did you wake up last night due to asthma symptoms? Yes/No 
 
 
 
